Asher Herzog

Associate
Full contact info

Experience

Centessa Pharmaceuticals – $380 Million IPO

May 28, 2021

Cooley advised the underwriters on Centessa Pharmaceuticals’ $380 million initial public offering of 18,975,000 American depositary shares ADSs, which includes the full exercise of the underwriters’ option to purchase additional shares. Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, Jefferies LLC and Evercore Group LLC, acted as joint book-running managers for the offering. Centessa Pharmaceuticals, whose securities now trade on the Nasdaq Global Select Market under the symbol “CNTA,” is a clinical-stage company employing its asset-centric business model to discover, develop and deliver impactful medicines to patients. Partners Div Gupta, Claire Keast-Butler, Josh Kaufman and Geoffrey Starr led the Cooley team.

Related contacts

Div Gupta
Partner, New York
Claire Keast-Butler
Partner, London
Josh Kaufman
Partner, New York
Sam Meiklejohn
Associate, London
Asher Herzog
Associate, New York
Jayne M. Munger
Associate, New York

Related Practices & Industries

Crinetics Pharmaceuticals – $75 Million Follow-on Offering

April 8, 2021

Cooley advised the underwriters on Crinetics Pharmaceuticals’ $75 million follow-on offering, with SVB Leerink acting as sole bookrunning manager. Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Partner Daniel Goldberg led the Cooley team.

Related contacts

Daniel I. Goldberg
Partner, New York
Malin Delling
Special Counsel, Los Angeles Downtown
Asher Herzog
Associate, New York

Related Practices & Industries

Kadmon Holdings – $240 Million Convertible Notes Offering

February 12, 2021

Cooley advised Kadmon Holdings on its offering of $240 million principal amount of 3.625% convertible senior notes due 2027. Kadmon Holdings, whose securities trade on the Nasdaq Global Select Market  under the symbol KDMN, is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Partners Eric Blancard, Mischi a Marca and Jason Savich led the Cooley team.

Related contacts

Eric Blanchard
Partner, New York
Mischi a Marca
Partner, San Francisco
Jason Savich
Partner, San Francisco
Reid Hooper
Special Counsel, Washington DC
Matthew S. Scarano
Associate, San Diego
Asher Herzog
Associate, New York
Molly Niffenegger
Associate, San Francisco

Related Practices & Industries

Billtrust to Combine With South Mountain, a Special Purpose Acquisition Company, at $1.3 Billion Value

November 25, 2020

Cooley advised Billtrust, a leading provider of cloud-based software and integrated payment processing solutions that simplify and automate B2B commerce, on its agreement to combine with South Mountain Merger Corporation, a publicly traded special purpose acquisition company or SPAC. The combined company will continue as a publicly listed entity and have an implied estimated enterprise value of approximately $1.3 billion at closing. Partners Miguel Vega, Nicole Brookshire and Matt Browne led the Cooley team advising Billtrust.

Read more

Related contacts

Miguel J. Vega
Partner, Boston
Matt Browne
Partner, San Diego
Alessandra Murata
Partner, Palo Alto
Randy Sabett
Special Counsel, Washington DC
Asher Herzog
Associate, New York
Pat Argenio
Associate, Boston
Eric Popp
Associate, Boston
Charles York
Associate, New York
Patrick Sharma
Associate, Los Angeles Santa Monica
Thomas Connors
Partner, Boston
Danielle Crinnion
Associate, Boston

Related Practices & Industries

Orphazyme – $84 Million IPO

October 2, 2020

Cooley advised Orphazyme on its $83.8 million initial public offering. Orphazyme, whose American depositary shares now trade on the Nasdaq Global Select Market under the symbol ORPH and ordinary shares trade on Nasdaq Copenhagen under the symbol ORPHA, is a Danish late-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of neurodegenerative orphan diseases. Partners Josh Kaufman and Div Gupta and senior associate Mark Ballantyne led the Cooley team.

Related contacts

Josh Kaufman
Partner, New York
Div Gupta
Partner, New York
Mark Ballantyne
Partner, Reston
Darah Protas
Associate, Washington DC
Asher Herzog
Associate, New York
Rasha Printz
Associate, Reston

Related Practices & Industries

View more